Digital transformation has long been a priority for all life science companies and it has been made even more pressing by the current health emergency caused by COVID-19.
New rare disease treatments face a complex market access landscape that presents fundamental challenges for pharmaceutical companies seeking to achieve launch excellence.
After a slow couple of years, there are signs that biotech M&A activity is coming back into vogue, and a series of small transactions announced in the last few days pr